Clinical trials: Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid Arthritis (RA)
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
The study objective of Period 1 was to compare the safety and efficacy of upadacitinib 15 mg once daily (QD) to abatacept on a background of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the…
- Trial name
- NCT03086343
- Testing
- Abatacept, Upadacitinib
- Where
- 161 sites in United States, Argentina and 28 more
- Volunteers
- 657 people
- Sponsor
- AbbVie
Rheumatoid Arthritis
Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate
The purpose of this study is to evaluate the efficacy and safety of namilumab in combination with existing methotrexate (MTX) therapy over 24 weeks in participants with moderate to severe early rheumatoid arthritis (RA)…
- Trial name
- TELLUS (NCT02393378)
- Testing
- Namilumab, Adalimumab, Methotrexate
- Where
- 13 sites in Czechia, Estonia and 3 more
- Volunteers
- 7 people
- Sponsor
- Takeda
Rheumatoid Arthritis
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
- Trial name
- NCT04171414
- Testing
- CT-P17 SC AI (adalimumab)
- Where
- Poland
- Volunteers
- 62 people
- Sponsor
- Celltrion
Rheumatoid Arthritis
A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis
This study is to evaluate the efficacy and safety of different doses of JAK1 inhibitor SHR0302 in subjects with moderate to severe active rheumatoid arthritis who had inadequate response to conventional synthetic DMARDs.
- Trial name
- NCT04333771
- Testing
- SHR0302
- Where
- China
- Volunteers
- 566 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Rheumatoid Arthritis
Safety and Pharmacokinetics Study of XOMA 052 in Subjects With Active, Stable, Moderate to Severe Rheumatoid Arthritis
Study X052070 will evaluate the safety and pharmacokinetics (PK) of XOMA 052 administered to patients with active, stable, moderate to severe rheumatoid arthritis (RA).
- Trial name
- NCT00777816
- Testing
- XOMA 052
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- XOMA (US) LLC
Rheumatoid Arthritis
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs.
This multi-center, open-label, single-arm, Phase IIIb study will evaluate the safety and efficacy of subcutaneous RoActemra/Actemra alone or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in…
- Trial name
- NCT02011334
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 25 sites in Argentina, Brazil and 4 more
- Volunteers
- 285 people
- Sponsor
- Hoffmann-La Roche
Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis
Korean Post-marketing Surveillance for Xeljanz XR
Xeljanz XR extended-release tablets 11 mg (Tofacitinib citrate) is a drug subject to the risk management plan in accordance with Article 4-1-11 of the "Regulation on Safety of Medicinal Products, etc." in Korea.
- Conditions
- Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis
- Trial name
- XRPMS (NCT04876781)
- Testing
- Tofacitinib XR
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Pfizer
Rheumatoid Arthritis, Psoriatic Arthritis
A Study of SPY072 in Rheumatic Disease
This is a multi-center, double-blind, placebo-controlled, Phase 2, proof-of-concept basket study with the goal of assessing the efficacy and safety of SPY072 compared to placebo in adults (aged ≥18 years) with rheumatic disease…
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases
- Trial name
- SKYWAY-RD (NCT07148414)
- Testing
- SPY002-072
- Where
- 64 sites in United States, Bulgaria and 6 more
- Volunteers
- 285 people
- Sponsor
- Spyre Therapeutics, Inc.
Rheumatoid Arthritis
Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Participants (DARWIN1)
Participants suffering from active rheumatoid arthritis despite continued treatment with methotrexate were evaluated for improvement of disease activity (efficacy) when taking GLPG0634 (3 different doses - 50 milligram [mg], 100…
- Trial name
- DARWIN1 (NCT01888874)
- Testing
- GLPG0634
- Where
- 142 sites in United States, Argentina and 20 more
- Volunteers
- 599 people
- Sponsor
- Lakefront Biotherapeutics NV
Rheumatoid Arthritis
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
The primary objective is to compare the safety and efficacy of multiple doses of ABT-494 versus placebo in moderately to severely active RA subjects on stable background MTX therapy with inadequate response or intolerance to…
- Trial name
- NCT01960855
- Testing
- ABT-494
- Volunteers
- 276 people
- Sponsor
- AbbVie
Arthritis, Rheumatoid
Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid Arthritis
This is a secondary structured database observational study conducted in Rheumatoid Arthritis (RA) patients treated with biologic and nonbiologic DMARDs, including tofacitinib, collected as part of the CorEvitas Japan RA…
- Trial name
- NCT05572567
- Where
- Japan
- Volunteers
- 1,972 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Study Evaluating Gerilimzumab´s Safety/Efficacy for Patients MTX or TNFα Antagonist Failed in Rheumatoid Arthritis
Phase 2 Study Evaluating Gerilimzumab's Safety/Efficacy for Patients with an Inadequate Response to MTX or a TNFα Antagonist in Rheumatoid Arthritis.
- Trial name
- NCT02795299
- Testing
- Gerilimzumab, Methotrexate, Folic Acid
- Sponsor
- Bird Rock Bio, Inc.
Rheumatoid Arthritis (RA)
TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs
This is a randomized, double-blind, placebo-controlled parallel-group Phase II study. The study aims to evaluate the efficacy and safety of TLL-018 in adult patients with moderate to severe active rheumatoid arthritis who have…
- Trial name
- NCT07748728
- Testing
- TLL-018
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Hangzhou Highlightll Pharmaceutical Co., Ltd
Arthritis, Rheumatoid
Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase Inhibitor
Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe Rheumatoid Arthritis.
- Trial name
- NCT05198310
- Testing
- KPL-404
- Where
- 42 sites in United States, Bulgaria and 5 more
- Volunteers
- 145 people
- Sponsor
- Kiniksa Pharmaceuticals, Ltd.
Rheumatoid Arthritis
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
To compare the maintenance of efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with or without other disease modifying antirheumatic drugs therapy with that of methotrexate with or without other…
- Trial name
- NCT01578850
- Testing
- Etanercept
- Where
- 62 sites in Brazil, China and 17 more
- Volunteers
- 491 people
- Sponsor
- Pfizer
Rheumatoid Arthritis
Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA
This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα therapy.
- Trial name
- NCT05246280
- Testing
- TC99m-tilmanocept
- Where
- 13 sites in United States
- Volunteers
- 169 people
- Sponsor
- Navidea Biopharmaceuticals
Rheumatoid Arthritis
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy
This observational study will evaluate the safety, tolerability and efficacy of tocilizumab in participants with moderate to severe RA who have an inadequate response to current non-biologic DMARD and/or anti-TNF therapy.
- Trial name
- NCT01362062
- Testing
- Tocilizumab
- Where
- 7 sites in India
- Volunteers
- 110 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study in Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to determine whether baricitinib is superior to placebo in the treatment of participants with moderately to severely active Rheumatoid Arthritis (RA) who have had an inadequate response to…
- Trial name
- RA-BEAM (NCT01710358)
- Testing
- Adalimumab, Baricitinib, Methotrexate
- Where
- 213 sites in United States, Argentina and 26 more
- Volunteers
- 1,307 people
- Sponsor
- Eli Lilly and Company
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
This 3 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo, both in combination with methotrexate (MTX).
- Trial name
- NCT00106548
- Testing
- tocilizumab [RoActemra/Actemra], Methotrexate
- Where
- 74 sites in Argentina, Australia and 15 more
- Volunteers
- 623 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis
Clinical trial to compare treatment with GP2017 and Humira® in patients with Rheumatoid Arthritis
- Trial name
- ADMYRA (NCT02744755)
- Testing
- Adalimumab - GP2017, Adalimumab - US licensed Humira
- Where
- 83 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Sandoz